Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Study on the Use of Simoctocog Alfa and Emicizumab for Surgery in Patients with Severe Hemophilia A

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of Hemophilia A, a genetic disorder that affects the blood's ability to clot properly. The study involves the use of a medication called Nuwiq, which is a form of Coagulation Factor VIII. This medication is administered as a solution for injection and is used in combination with another medication called Emicizumab, which is already being used regularly by the patients participating in the study.

The purpose of the study is to evaluate how effective Nuwiq is in managing bleeding during and after major surgery in patients with severe Hemophilia A who are already on Emicizumab prophylaxis. Participants will receive Nuwiq through an intravenous injection, which means it is delivered directly into a vein. The study will monitor the patients' response to the treatment over a period of time, focusing on how well the medication helps control bleeding during surgery.

Throughout the study, researchers will assess the overall success of the treatment by observing the patients' bleeding control during surgery and any side effects that may occur. The study will also track the levels of Coagulation Factor VIII in the blood before and after the Nuwiq injections. The trial is expected to continue until March 2025, providing valuable insights into the effectiveness of this treatment approach for individuals with severe Hemophilia A.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the trial

    Upon joining the study, you will be informed about the trial's purpose, which is to evaluate the effectiveness of Nuwiq in combination with ongoing emicizumab treatment for managing bleeding during major surgery in patients with severe haemophilia A.

  2. Step 2

    Pre-surgery preparation

    Before your surgery, you will continue your regular emicizumab treatment. You will also receive Nuwiq through an intravenous injection. The specific dosage will depend on your individual needs and will be determined by the medical team.

  3. Step 3

    Surgery day

    On the day of your surgery, you will receive Nuwiq injections before and after the procedure. The medical team will monitor your FVIII levels, which are important for blood clotting, to ensure they are at the right levels for surgery.

  4. Step 4

    Post-surgery monitoring

    After your surgery, the medical team will continue to monitor your condition closely. You will receive additional Nuwiq injections as needed to maintain proper blood clotting. Your response to the treatment will be assessed using a scale to determine its effectiveness.

  5. Step 5

    Follow-up assessments

    Throughout the trial, you will have regular follow-up visits to assess your health and the effectiveness of the treatment. The medical team will check for any side effects or complications, such as the formation of inhibitors against FVIII or any thrombotic events.

Who can join the trial?

5 criteria

  • Must have severe haemophilia A. This means having very low levels of a protein called factor VIII (less than 1%) in the blood, according to medical history.
  • Must be a male who is at least 12 years old.
  • Must have been treated with any factor VIII product for at least 150 exposure days. An exposure day is any day you receive treatment with factor VIII.
  • Must be on regular preventive treatment with a medication called emicizumab for at least 3 months before a planned major surgery that requires factor VIII treatment.
  • Must provide written informed consent. This means you agree to participate in the study after being fully informed about it.

Who cannot join the trial?

3 criteria

  • Patients who do not have severe haemophilia A cannot participate. Severe haemophilia A is a condition where the blood does not clot properly, leading to excessive bleeding.
  • Only male patients can participate. Female patients are not eligible.
  • Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups like children, pregnant women, or those unable to give consent.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Nuwiq

    is a medication used to help control bleeding in people with hemophilia A, a condition where the blood does not clot properly. It works by providing a protein that is missing in people with this condition, which helps the blood to clot and stop bleeding. In this trial, Nuwiq is being used to manage bleeding during and after surgery in patients who are already receiving another treatment called emicizumab.

  • Emicizumab

    is a medication used to prevent bleeding in people with hemophilia A. It works by helping the blood to clot more effectively, reducing the risk of bleeding episodes. In this study, emicizumab is being used as a regular treatment to prevent bleeding, and its effectiveness is being evaluated in combination with Nuwiq during surgical procedures.

What is already known about the treatment

Nuwiq – Nuwiq is administered as an injection and is used in combination with another medication called emicizumab to help manage bleeding in patients with severe Haemophilia A, especially during major surgeries. Currently, Nuwiq is being studied for its effectiveness in this specific use, and it is recognized in medical literature as a treatment option for Haemophilia A. The main therapeutic indication for Nuwiq is to prevent and control bleeding episodes in people with this condition. At the molecular level, Nuwiq works by replacing the missing or defective factor VIII, a protein that is essential for blood clotting. It is classified pharmacologically as a recombinant factor VIII product.

Investigated diseases

Haemophilia A – Haemophilia A is a genetic bleeding disorder caused by a deficiency of clotting factor VIII. This deficiency leads to prolonged bleeding after injuries, surgery, or even spontaneously in severe cases. The disease primarily affects males, as it is linked to the X chromosome. Individuals with Haemophilia A may experience frequent nosebleeds, easy bruising, and joint bleeds, which can cause pain and swelling. Over time, repeated joint bleeds can lead to joint damage and reduced mobility. The severity of the disease varies depending on the level of factor VIII activity in the blood.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-502060-21-00Protocol codeGENA-22Estimated enrolment50 patientsSponsorOctapharma AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).